Prediction of the response to chemotherapy in ovarian cancers

• Autorzy: Surowiak P
• Języki publikacji: EN

Abstrakty

EN

Ovarian cancer represents the fifth most frequent cause of death as a result of malignant processes after cancers of the breast, large intestine, lung and stomach. Owing to the localisation of ovarian cancer, approximately 75% of cases are diagnosed at the III and IV stages of advancement according to FIGO. Because of the advanced stage of the disease surgery has to be followed by chemotherapy in most cases of ovarian cancer and therefore resistance to cytostatic drugs represents a major clinical problem. The potential to predict the response to therapy with the use of cytostatic drugs would enable the most effective drugs to be applied in individual cases, thus improving the efficiency of the treatment and restricting the development of resistance to cytostatic drugs. In the present paper the progress made so far in the prediction of the clinical course of ovarian cancer is reviewed. The significance of the expression of the ATP-binding cassette (ABC) transporters is described, including P-glycoprotein and MRP2, the principal representatives of the protein group. The importance of disturbed control of apoptosis and the overexpression of HER-2 and topoisomerase 1A are also discussed. Two sections are devoted to the most recent studies in the biology of ovarian cancer, pangenomic studies on gene expression using DNA microarrays and aberrations of DNA methylation.

Słowa kluczowe

EN

prediction; response; chemotherapy; ovarian cancer; cancer; multidrug resistance

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2006
• Tom: 65
• Numer: 4
• Strony: 285-294
• Opis fizyczny: p.285-294,fig.,ref.

Twórcy

autor

Surowiak P

• University School of Medicine, Wroclaw, Poland

Bibliografia

• 1. Allen JD, Schinkel AH (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther, 1: 427–434.
• 2. Arts HJG, Katsaros D, de Vries EGE, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemese PHB, van der Zee AGJ, Suurmeijer AJH (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res, 5: 2798–2805.
• 3. Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS, Zuber K, Karnell LH, Winchester DP (1993) National survey of ovarian carcinoma. 1. A patient care evaluation study of the Amercian College of Surgeons. Cancer, 71: 1629–1638.
• 4. Baker E, El-Osta A (2003) The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res, 290: 177–194.
• 5. Beeghly A, Katsaros D, Chen H, Fraccholi S, Zhang Y, Massorbio M, Risch H, Jones B, Yu H (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol, 100: 330–337.
• 6. Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer, 5: 231–237.
• 7. Cannistra SA (2004) Cancer of the ovary. N Engl J Med, 351: 2519–29.
• 8. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD (2003) Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res, 63: 8097–8102.
• 9. Duan Z, Lamendola DE, Cuan Y, Yusuf RZ, Seiden M (2005) Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol, 55: 277–285.
• 10. Esteller M (2005) Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol, 45: 629–656.
• 11. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G, Benard J (1996) Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer, 68: 67–74.
• 12. Ferrandina G, Fagotti A, Salerno MG (1999) p53 over-expression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer, 81: 733–740.
• 13. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev, 2: 48–58.
• 14. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med, 53: 615–27.
• 15. Gumiński AD, Balleine RL, Chiew Y-E, Webster LR, Tapner M, Farrel GC, Harnett PR, DeFazio A (2006) MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol, 100: 239–246.
• 16. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M, Lage H (2006) Resistance prediction profile for eleven anticancer agents at clinical concentrations based on the gene expression pattern of thirty cell lines. Int J Cancer, 118: 1699–1712.
• 17. Hamer DH (1986) Metallothionein. Annu Rev Biochem, 55: 913–951.
• 18. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iatchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res, 11: 2149–2155.
• 19. Havrilesky L, Darcy KM, Hamdan H (2003) Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol, 21: 3814–3825.
• 20. Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M, Tachibana M, Nagasue N (1997) Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Lab Invest, 54: 342–347.
• 21. Husain I, Mohler JL, Seigler HF, Besterman JM (1994) Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res, 54: 539–546.
• 22. Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, Shimizus M, Minanami H, Sakuragi N (2003) Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II–IV ovarian cancer. Int J Gynecol Cancer, 13: 776–784.
• 23. Jazaeri AA, Awtrey CS, Chandramouli GVR, Chuang YE, Khan J, Sotiriou C, Aprelkova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J (2005) Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancer. Clin Cancer Res, 11: 6300–6310.
• 24. Jia P, Wu S, Li F, Xu Q, Wu M, Chen G, Liao G, Wang S, Zhou J, Lu Y, Ma D (2005) Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Int J Gynecol Cancer, 15: 1042–1048.
• 25. Katsaros D, Fracchioli S, Arts HJ, de Vries EG, Danese S, Richiardi G, Arisio R, Gordini G, van der Zee AG, Suurmeijer AJ, Massobrio M (1999) Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma. Minerva Ginecol, 51: 463–470.
• 26. Kawiak J, Zabel M (2002) Seminaria z cytofizjologii. Urban & Partner, Wrocław.
• 27. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res, 57: 3537–3547.
• 28. Kowalski P, Surowiak P, Lage H (2005) Reversal of drug-resistant phenotypes by an autocatalytic multitarget multirybozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther, 11: 1393–1398.
• 29. Kupryjanczyk J, Bell D, Dimeo D (1995) p53 gene analysis of ovarian bordeline tumors and stage I carcinomas. Hum Pathol, 26: 387–392.
• 30. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol, 121: 172–176.
• 31. Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst, 97: 1498–1506.
• 32. Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol, 94: 152–160.
• 33. McCluggage WG, Strand K, Abdulkair A (2002) Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumours. Int J Gynecol Cancer, 12: 62–65.
• 34. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AG, Kaye SB, Brown R, Keith WN (1994) Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer, 59: 607–611.
• 35. Patel VA, Dunn MJ, Sorokin A (2002) Regulation of MDR1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem, 227: 38915–38920.
• 36. Perego P, Gatti L, Righetti SC, Bereta GL, Carenini N, Corna E, Bo LD, Tineli S, Cloangelo D, Leone R, Apostoli P, Lombardi L, Beggiolini G, Piazzoni L, Zunino F (2003) Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer, 105: 617–624.
• 37. Plisiecka-Hałasa J, Karpińska G, Szymańska T, Ziółkowska I, Mądry R, Timorek A, Dębniak J, Ułańska M, Jedryka M, Chudecka-Głaz A, Klimek M, Rembiszewska A, Kraszewska E, Dybowski B, Markowska J, Emerich J, Płużańska A, Goluda M, Rzepka-Górska I, Urbański K, Zieliński J, Stelmachów J, Chrabowska M, Kupryjańczyk J (2003) P21WAF1, p27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinumbased regimens. Annals Oncol, 14: 1078–1085.
• 38. Qiu YY, Mirkin BL, Dwivedi RS (2005) Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Det Prev, 29: 456–463.
• 39. Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ (2000) Clinical use of topoisomerase inhibitors in anticancer treatment. Med Ped Oncol, 35: 382–402.
• 40. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A (2004) ABCG2 — a transporter for all seasons. FEBS Letters, 567: 116–120.
• 41. Satoh T, Nishida M, Tsunoda H, Kubo T (2001) Expression of glutathione S-transferase pi (GST-pi) in human ovarian tumors. Eur J Obstet Gynecol Reprod Biol, 96: 202–208.
• 42. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22: 7265–7279.
• 43. Slamon D, Clark G (1988) Amplification of C-ERB-B2 and agressive breast tumors? Science, 240: 1795–1798.
• 44. Spentoz D, Levine DA, Kolia S, Out H, Boyd J, Libermann TA, Cannistra SA (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol, 23: 7911–7917.
• 45. Spentoz D, Levine DA, Ramoni MF, Joseph, M, Gu X, Boyd J, Lbermann TA, Cannistra SA (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol, 22: 4700–4710.
• 46. Surowiak P, Kaplenko I, Spaczyński M, Zabel M (2003) Expression of metallothionein (MT) and intensity of proliferation in ovarian cancers treated with cisplatin and paclitaxel. Fol Morphol, 62: 493–495.
• 47. Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczynski M, Dietel M, Zabel M, Lage H (2006) Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Letters, 235:272–280.
• 48. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M (2005) Augmented expression of metallothionein and glutathione S-transferase pi as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Archiv, 447: 626–633.
• 49. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M (2006) Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol, 25: 131–139.
• 50. Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dolińska-Krajewska B, Gębarowska E, Dietel M, Zabel M, Lage H (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res [in press].
• 51. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M, Lage H (2005) Relationship between cyclooxygenase 2 and P-glycoprotein expressions in invasive breast cancers and their prognostic significance. Breast Cancer Res, 7: R862–R870.
• 52. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res, 56: 4124–4129.
• 53. Teodoridis JM, Strathdee G, Plumb JA, Brown R (2004) CpG-island methylation and epigenetic control of resistance to chemotherapy. Biochem Soc Transactions, 32: 916–917.
• 54. Verkis A, Meynard D, Haaz M-C, Bayssas M, Bonnet J, Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res, 64: 356–362.
• 55. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nature Reviews. Drug Discovery, 4: 307–320.
• 56. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol, 3: 430–440.
• 57. Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel. Drug Resistance Updates, 7: 227–232.
• 58. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu R (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol, 96: 287–295.
• 59. Wirgley E, Verspaget HW, Jayson GC, McGown AT (2000) Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol, 126: 717–721.
• 60. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB (2006) Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol, 100: 152–159.
• 61. Yoh K, Ishii G, Yokose, T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res, 10: 1691–1697.
• 62. Zabel M, Kaczmarek A, Ramlau R, Matecka-Nowak M (1991) Rola P-glikoproteiny w wielolekowej oporności nowotworów na cytostatyki. Nowotwory, 41: 32–45.
• 63. Zasławski R, Surowiak P, Zabel M (2005) Classical and novel molecular prognostic factors in ovarian cancers. Pol Merk Lek, 114: 105–111.